News ·
Neurawave receives additional investment
Neurawave has received additional investment, which lets us take the next step toward making our migraine treatment available to more people.
Kalmar, Sweden, June 26, 2025 — We are happy and proud to announce that Neurawave has received additional investment. It means we can take the next big step toward making our migraine treatment available to more people.
Thank you to all the investors, advisers and supporters who believe in our vision:
- Migraine treatment without medication
- Personal treatment, built with AI
- Freedom to live without migraine running your everyday life
And thank you to Kalmar Science Park for supporting our journey. Read more in Kalmar Science Park's article about the investment (in Swedish).
We are moving on with even more energy and a clear goal: a future without migraine.
About Neurawave
Neurawave AB is a Swedish company in Kalmar that develops Relivia, a device for people living with migraine, and the Relief aHead app. Relivia is sold in Chile under the Relief aHead brand.
Press contact
press@reliefahead.com · neurawave.se
We reply during Swedish office hours, Monday to Friday.